A contract to manufacture DNA-based flu vaccine has been awarded to the Waisman Clinical BioManufacturing Facility at UW-Madison’s Waisman Center.
The vaccine will be tested first on animals, with human testing expected to begin early next year during the flu season, said Allen D. Allen, chief executive of CytoDyn of Santa Fe, N.M., which developed the vaccine.
Office of Strategic Communication